Literature DB >> 2726152

Reduced toxicity of intravitreally injected liposome-encapsulated cytarabine.

K R Liu1, G A Peyman, S C She, M R Niesman, B Khoobehi.   

Abstract

Cytarabine has been demonstrated to be a more potent inhibitor of fibroblast proliferation than fluorouracil. It is, however, more toxic to the retina. We evaluated the ocular toxicity of liposome-encapsulated cytarabine in vitrectomized and nonvitrectomized rabbit eyes by ophthalmic and histopathologic examination. In the vitrectomized group, doses of up to 26 micrograms were nontoxic to the retina. In nonvitrectomized eyes, doses of up to 55 micrograms were nontoxic. Doses of 85 micrograms resulted in loss of ganglion cells and disorganization of photoreceptor cells. The results obtained in this study demonstrated a substantial reduction in ocular toxicity of liposome-encapsulated cytarabine, as compared with a previous study which employed free drug. By virtue of its reduced toxicity, cytarabine in a liposomal vehicle may be of value in the treatment of ocular proliferative disorders.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2726152

Source DB:  PubMed          Journal:  Ophthalmic Surg        ISSN: 0022-023X


  6 in total

Review 1.  Clinical pharmacokinetics of cytarabine formulations.

Authors:  Akinobu Hamada; Takeo Kawaguchi; Masahiro Nakano
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Toxicity of 1-(beta-D-arabinofuranosyl)cytosine after intravitreal injection in the rabbit eye.

Authors:  J J Diets-Ouwehand; R J de Keizer; G F Vrensen; S Groen-Jansen; J A van Best
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

3.  Liposomally-entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients. Eperimental toxicity and pharmacokinetics, and clinical trial.

Authors:  M Díaz-Llopis; M J Martos; E España; M Cervera; A O Vila; A Navea; F J Molina; F J Romero
Journal:  Doc Ophthalmol       Date:  1992       Impact factor: 2.379

4.  Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages.

Authors:  Y N Hui; H C Liang; Y S Cai; B Kirchhof; K Heimann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-02       Impact factor: 3.117

Review 5.  Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Authors:  S Kim
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

6.  Suppression of experimental proliferative vitreoretinopathy by sustained intraocular delivery of 5-FU.

Authors:  H Borhani; G A Peyman; M H Rahimy; H Thompson
Journal:  Int Ophthalmol       Date:  1995       Impact factor: 2.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.